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Colorectal carcinoma invading the submucosa but not the muscular layer (pT1, early inva-
sive cancer) represents the earliest form of clinically relevant colorectal cancer in most
patients. Neoplastic invasion of the submucosa, in fact, opens the way to metastasis via
the lymphatic and blood vessels, and the choice between surveillance and major surgery
will turn on its metastatic potential. The following histological features predict the risk
of metastasis and the different clinical outcomes: grade of differentiation of carcinoma,
lymphovascular invasion, state of the resection margin. Microstaging of invasive cancer,
namely the width and the depth of submucosal invasion, together with tumor budding
at the advancing edge allow the metastatic risk to be further stratiﬁed in minimal, low,
and high. Different, although morphologically undistinguishable, tumorigenic pathways are
supposed to lead to the malignant transformation of colonic mucosa and subsequently
to drive the progression from early to advanced cancer: new biomarkers are needed to
identify progressive and non-progressive pT1 neoplasia.
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THE METASTATIC PHENOTYPE IN COLONIC TUMORIGENESIS
According to the well recognized adenoma–carcinoma sequence,
colorectal neoplasia is a single, indivisible continuum that, from
a morphological point of view, begins within the mucosa as mild
dysplasia and can progress through dysplasia of increasing severity
until invasion across themuscularismucosae occurs, at which time
the term carcinoma applies (Hamilton et al., 2010). This deﬁnition
of adenocarcinoma excludes diagnosis of intramucosal carcinoma
in the colon or rectum, in contrast to the accepted deﬁnitions for
the stomach, esophagus, and small bowel: in the latter cases, a
decision on surgical versus local therapy is made based on respec-
tive protocols. Comparable lesions in the colon and rectum are
reported as high grade mucosal neoplasia, because a carcinoma
in the colon is deﬁned by inﬁltration of the submucosa (Vieth
et al., 2011), and colorectal lesions harboring “in situ” or “intra-
mucosal” carcinoma are neither regarded nor treated as malignant
ones (Figure 1).
Conﬁrmatively, there are no known reliable examples of purely
intramucosal or intraepithelial carcinomas arising in adenomas
which have given rise to lymphatic metastasis, and no metasta-
tic disease was found arising in cases of isolated, even if poorly
differentiated, intramucosal colorectal carcinoma (Lewin et al.,
2007).
The reason of this discrepancy has ﬁrstly to be ascribed to the
paucity of lymphatic vessels in the colonic mucosa. It has been
demonstrated, in fact, that no lymphatic channels can be seen
in the normal mucosa at a level higher than the lowest portion
of the crypt of Lieberkuhn, the vast majority of them maintain-
ing an intimate association with the muscularis mucosae. The
same relationship was found in the lamina propria of adeno-
matous polyps (Fenoglio et al., 1973), so that cancer cells must
invade at least at the level of the submucosa in order to permeate
importantly the lymphatic system. It is reasonable, however, that
additional factors in the molecular machinery of the metastatic
process are involved, besides the mere availability of lymphatics.
In this regard, the speciﬁc interactions between E-cadherin and
catenins occurring throughout the colorectal carcinogenesis can
modulate the cadherin-mediated cell adhesion system (Takayama
et al., 1996) and determine the potentials of invasiveness and
metastasis of cancer cells in the different layers of the intestinal
wall.
INVASION AND PSEUDO-INVASION
Repeated twisting of polyps, long stalked polyps above all, cause
displacement of adenomatous tissue, glands together with lam-
ina propria, through the muscularis mucosae into the submucosa.
This is referred as pseudo-invasion and, occurring in 2.3–11.4%
of polyps (Rossini et al., 1985), represents a major concern in the
differential diagnosis with respect to invasive carcinoma, in that
some patients with cancerised adenoma may require colectomy,
whereas adenomas with epithelial displacement are adequately
treated by endoscopic polypectomy. The presence or absence of
hemosiderin, desmoplastic reaction, or lamina propria enclos-
ing the glands are the main histological features distinguishing
pseudo-invasion from true invasion (Figure 2).
Hemosiderin in the lamina propria is found in 90% of polyps
with pseudo-invasion but also (though less frequently) in cases of
true invasion, so that hemosiderin deposition is not a completely
reliable criterion. The presence of lamina propria surrounding the
glands below the muscularis mucosae is a deﬁnitive indicator of
pseudo-invasion, whereas desmoplasia is a reliable criterion for
true invasion. Cystic dilation of submucosal glands and masses of
free mucus in the stroma are mainly attributable to mechanical
displacement.
Diagnosis is more difﬁcult when the submucosal glands dis-
play high grade dysplasia: under these circumstances, however,
immunohistochemical staining for p53, E-cadherin, MMP-1, and
collagen IV may be helpful (Yantiss et al., 2002).
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FIGURE 1 | Histologic section of a colonic adenoma containing
invasive carcinoma. High grade mucosal neoplasia is strictly conﬁned
above the muscularis mucosae, whereas well differentiated
adenocarcinoma extensively invades the submucosa (lower right corner).
CANCERISED ADENOMAS: PATHOLOGIC PREDICTORS AND
CLINICAL OUTCOMES
Colorectal adenomas containing early invasive carcinoma com-
prise a carcinoma invading the submucosa but not the muscular
layer (Stage pT1, according to the TNM system; Sobin et al., 2010).
They are a key stage in the large bowel tumor sequence since they
represent the earliest form of clinically relevant colorectal cancer
in most patients. Neoplastic invasion of the submucosa, in fact,
opens the way to metastasis via the lymphatic and blood vessels,
and the choice between surveillance and major surgery will turn
on their metastatic potential. Prevalence of pT1 cancer has been
steadily rising over the past two decades, mainly due to the wide-
spread use of colonoscopy and the improvement of polypectomy
techniques, accounting for as much as 11% of all endoscopically
removed polyps (Nusko et al., 1997). At present, histological para-
meters alone (grade of the invasive carcinoma, lymphovascular
invasion, state of the resection margin) determine whether a low
(7%) or high (35%) risk of metastasis exists (Coverlizza et al.,
1989).
Although most pT1 cancers display a low grade of differen-
tiation (well/moderately differentiated, G1–G2), 5–10% of cases,
associated with a higher incidence of adverse outcomes (Cooper
et al., 1998), are high grade cancers showing minimal or no tubule
formation and marked cytological atypia (poorly differentiated
adenocarcinoma/undifferentiated carcinoma, G3–G4; Washing-
ton et al., 2009). Tumor grade has been regarded as the most
valuable predictor of lymph node involvement (Volk et al., 1995;
Whitlow et al., 1997) and its evaluation is reliable when a high
grade of differentiation is applied to any area of the cancer display-
ing poor differentiation, independently of its extension (Quirke
et al., 2011).
Since cancers can spread to distant sites via the blood stream or
to the regional lymph nodes, via lymphatics, deﬁnite histological
FIGURE 2 | Displacement of glands beyond the muscularis mucosae
(“Pseudo-invasion”).The displaced glands are surrounded by lamina
propria and close to hemosiderin deposits.
detection of lymphatic invasion or venous tumor emboli is
thought to be associated with adverse outcomes. The predictive
value of vascular invasion, however, has been widely debated in
the literature (Jass, 1995; Kikuchi et al., 1995). Volk et al. (1995)
have denied the importance of vascular invasion, that actually
does not seem to be an independent risk factor at multivariate
analysis (Netzer et al., 1998; Masaki and Muto, 2000). No dif-
ferences in clinical outcomes were found pooling low-risk pT1
carcinomas with those with only vascular invasion (Hassan et al.,
2005), although lymphatic invasion in the absence of other his-
tologic risk factors is rarely found (Netzer et al., 1998). It has
to be taken into account that distinguishing true invasion of
endothelium-lined vascular spaces in the submucosa from retrac-
tion artifact around cancer cell aggregates is difﬁcult, could require
the additional use of immunohistochemistry (Ishikawa et al.,
2008; Suzuki et al., 2009; Quirke et al., 2011) and impair diag-
nostic reproducibility (Cooper, 2007). Ueno et al. (2004), how-
ever, have demonstrated that deﬁnite vascular invasion without
other unfavorable pathologic features is associated with an adverse
outcome.
The resection margin obtained by endoscopic polypectomy
is histologically indicated by a strip of coagulative necrosis (i.e.,
diathermy change) about 1mm thick. The presence of cancer cells
at or near the resection margin is a reliable histologic marker of
adverse outcome (Cooper, 1983, 2007; Coverlizza et al., 1989).
Frontiers in Oncology | Gastrointestinal Cancers March 2012 | Volume 2 | Article 22 | 2
Risio Early colorectal cancer
A negative margin is reported in the absence of cancer within
the diathermy, one high-power ﬁeld from diathermy, or more
than 1mm from the actual margin of resection (Cooper et al.,
1998).
The different histological risk factors can be further linked
with distinct clinical outcomes: a positive resection margin
is predictive of local disease, poorly differentiated carcinoma
of hematogenous metastasis and cancer-related mortality, and
vascular invasion of lymph node metastasis (Hassan et al.,
2005). Low- and high-risk cancers, therefore, do not only
differ in lymph node metastatic potential but also – and
even more importantly – as regards hematogenous metasta-
sis, mortality rates, and overall survival (Wang et al., 2005).
These observations clearly suggest that, following endoscopic
polypectomy, all the histological risk factors need to be care-
fully evaluated by the pathologist and that the classiﬁcation
of patients in low- and high-risk groups is clinically meaning-
ful.
It has been demonstrated that the level of cancer submucosal
invasion is associated with the lymph node metastatic potential
(Nascimbeni et al., 2002) and is important in predicting the out-
come of pT1 tumors. Haggitt et al. (1985) deﬁned the level of
invasion into the stalk of the polyp for pedunculated lesions,
and Kikuchi et al. (1995) the thirds of invasion (i.e., sm1, sm2,
sm3) into the submucosa of non-polypoid tumors. A quantitative
microstaging has also been proposed, measuring the depth and
the width of submucosal invasion of pT1 cancers, that effectively
predicts themetastatic potential (Ueno et al., 2004). At the present
time, a ﬁrm evidence-based recommendation for onemethod can-
not yet bemade, because of lack of consensus (Quirke et al., 2011).
It has to be noted, however, that the precise quantitative evaluation
of the submucosal invasion depth could enable us to distinguish
tumors with no orminimal risk of nodal involvement (i.e., a depth
of less than 500μm), although the proportion of tumors meeting
these conditions is too small to use these categories as the crite-
rion for a conservative approach (Ueno et al., 2004; Yasuda et al.,
2007).
More recently, a unique histologic feature, tumor budding
(namely the presence of scattered isolated single cells or small clus-
ter of undifferentiated cells at the advancing edge of the cancer),
has been demonstrated to be a reliable marker of the metastatic
potential of cancerised adenomas. Budding describes the biolog-
ical behavior of the tumor at the front of invasion in terms of
epithelial – mesenchymal interactions (Prall, 2007) and its abil-
ity to predict metastases compared with the previously identiﬁed
histologic factors has been proven (Hase et al., 1995; Okuyama
et al., 2002; Ueno et al., 2004; Kazama et al., 2006; Sohn et al.,
2007; Ishikawa et al., 2008; Ogawa et al., 2009; Suzuki et al.,
2009). Despite its prognostic value, there is a great heterogene-
ity in reporting tumor budding, and there is no consensus on the
assessment methods and cut-off values (Shinto et al., 2005; Wang
et al., 2009), limiting its clinical use.However, a recent study engag-
ing several multicentre, multinational investigators demonstrated
an overall fair level of diagnostic agreement for tumor budding
in colorectal cancer. In particular, diagnostic reproducibility was
signiﬁcantly improved in early cancer when using quantitative and
selective methods of evaluation of bud cells (Puppa et al., 2012).
The balancing between morbidity and mortality associated
with surgical resection and the risk of tumor progression after
endoscopic polypectomy should be the main-stay of clinical deci-
sion making in pT1 cancers (Cooper et al., 2012), taking into
account that post-operativemortality ranges 0.6–4.4%,depending
on the population, age of patient, and quality of services avail-
able (Quirke et al., 2011). While morphological markers are easily
identiﬁable but widely ranged, biomarkers are required that are
highly predictive of the events leading to the acquisition of the
metastatic phenotype of early colorectal cancers. It has been pre-
viously demonstrated that, in contrast to advanced cancer, the
metastatic potential of pT1 cancer is correlated neither with its
proliferative activity (Risio and Rossini, 1993; Jung et al., 2001),
nor with DNA ploidy (Risio et al., 1993). In the early stages, there-
fore, the metastatic potential is conceivable to be dependent on
multiple and sequential alterations of cell–cell, cell–matrix inter-
actions, and cell motility rather than on the derangement of cell
growth. Among the adhesion molecules expressed by cancer cells,
however, neither β-catenin nor claudins turned out to be related
to the lymph node status (Ishikawa et al., 2008).
STOCHASTIC MODELING OF EARLY CANCER
On the whole, two distinct proﬁles are identiﬁable in the nat-
ural history of cancerised adenomas, in terms not only of lymph
nodemetastases,but also of hematogenous spread, recurrence, and
mortality. This suggests the possibility that the malignant polyp
represents the end point of two different, although morpholog-
ically undistinguishable, tumorigenic, and genetic pathways, the
former blocking the growth of early cancer, the latter allowing its
fast progression toward advanced colorectal cancer (Hassan et al.,
2005).
Whenmalignant transformation of colonic intraepithelial neo-
plasia occurs, carcinoma has been thought to progress invariably,
from invasion of the submucosa (pT1 stage) through the exten-
sion to the deeper structures of the intestinal wall (i.e., “advanced
colorectal cancer,” pT2–pT4 stages). The transition pT1–pT4 has
therefore been conceived to be a continuous, progressive, irre-
versible process, which parallels the metastatic ratio and the
decreased survival of patients (Gunderson et al., 2010). Several
chromosome defects keep up with morphological evolution in
colorectal tumor progression. Whilst 1p deletions represent an
early event, numerical aberrations affecting chromosomes 7 and
18, 17p and 18q deletions were reported to be the most fre-
quent late-stage events. A stochastic model has been hypothesized,
in which the transition from early to advanced stages is prob-
abilistically regulated by the loss of subtelomeric region in 17p
(Risio et al., 2003). Early colorectal cancer with loss of chro-
mosome 17 actually represents the emergence from high grade
dysplasia adenomatous tissue of a cell clone with genetically
determined low proliferative levels, low DNA aneuploidy evolu-
tion rates and tendency to stabilize without further increase of
the tumor stage. The opposite is true for pT1 colorectal cancers
with 17p deletions, in which the invasion of the submucosa is
likely to represent a fast transition toward the progressive inva-
sion of cancer through the intestinal wall. Further research should
deﬁne the biopathological features of non-progressive cancerised
adenomas.
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CONCLUDING REMARKS
Cancerised adenomas (pT1 cancers) represent the earliest form
of clinically relevant colorectal cancer in most patients. Invasion
of the submucosa opens the way to metastasis and the choice
between endoscopic surveillance andmajor surgery turns on their
metastatic potential. At present, histologic features alone are pre-
dictive of the metastatic risk and clinical outcomes. Genetic and
epigenetic events drive the growth and progression of pT1 can-
cers, and are worthy of being intensively investigated in order to
improve the management of patients with early cancer.
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